Form 4: Bausch + Lomb Exec Gains 6,146 Shares

Bausch + Lomb's President of Surgical, Luc Bonnefoy, acquired 6,146 common shares from performance stock units, reflecting met performance targets.

Summary

• Luc Bonnefoy, President, Surgical at Bausch + Lomb Corp (BLCO), acquired 6,146 common shares.
• These shares are derived from Performance Stock Units (PSUs) originally granted on March 1, 2023, under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan.
• The applicable performance conditions for these PSUs were satisfied at the target performance level (100%) as of August 5, 2025.
• The earned PSUs are scheduled to vest on March 1, 2026, contingent upon Mr. Bonnefoy's continued employment through that date.
• Following this transaction, Luc Bonnefoy beneficially owns a total of 77,362 common shares.

Sentiment

Score: 7

Explanation: The filing indicates that performance conditions for executive PSUs were met at the target level, which is a positive sign of company performance and executive alignment, though it's a routine compensation event and not a major catalyst.

Positives

• Performance conditions for the executive's PSUs were met at the target level (100%), indicating successful achievement of pre-defined company goals.
• The acquisition of shares by a key executive, Luc Bonnefoy, aligns his financial interests more closely with those of the company's shareholders.

Future Outlook

The earned PSUs are set to vest on March 1, 2026, provided the reporting person maintains continued employment through that date, indicating a future milestone for executive compensation.

Industry Context

This Form 4 filing represents a routine insider transaction related to executive compensation. It reflects standard practices within the pharmaceutical and medical device industry, where performance-based equity awards are commonly used to incentivize long-term executive alignment with company strategic and financial goals.

Comparison to Industry Standards

• The use of Performance Stock Units (PSUs) with performance conditions and a vesting schedule is a common executive compensation practice across large pharmaceutical and medical device companies, similar to those employed by peers such as Johnson & Johnson, Medtronic, or Abbott Laboratories.
• The satisfaction of performance conditions at the target level is a standard outcome for well-designed incentive plans, indicating the company's performance met the pre-established criteria for this award.

Stakeholder Impact

• Shareholders: The transaction demonstrates alignment of executive incentives with company performance and increases insider ownership.
• Employees: Reinforces the company's commitment to performance-based compensation structures for its leadership.

Next Steps

• The 6,146 common shares are expected to vest on March 1, 2026, contingent on Luc Bonnefoy's continued employment.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event where performance stock units vested because performance conditions were met at the target level. While it indicates positive internal performance and executive alignment, it does not present new information that would fundamentally alter the investment thesis for Bausch + Lomb. It's a standard operational disclosure rather than a catalyst for significant price movement, thus a 'hold' recommendation is appropriate as it doesn't provide a strong reason to buy or sell based solely on this filing.

Keywords

Bausch + Lomb, BLCO, Insider Trading, Form 4, Performance Stock Units, Executive Compensation, Share Acquisition, Luc Bonnefoy, Surgical Division